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In the revised World Health Organization classification 2016, anaplastic pleomorphic xanthoastrocytoma (PXA) has been newly defined as a variant of the PXA entity.
Furthermore, some anaplastic PXA were reported to have extremely poor prognosis which showed a type of pediatric glioblastoma (GBM) molecular profile. Recent integrated molecular classification for primary central nervous system tumors proposed some differences between histological and molecular features. Herein, in a genomewide molecular analysis, we show an extreme aggressive anaplastic PXA that resulted in a pediatric GBM molecular profile. A full implementation of the molecular approach is the key to predict prognosis and decide the treatment strategy for anaplastic PXA.
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Pleomorphic xanthoastrocytoma is a primary brain tumor categorized as WHO grade 2 with a predilection for the temporal lobe in pediatric and young adult patients. 1 PXA have generally favorable prognoses with a 10-year survival probability of over 70%. (Table S3 ). We conducted a 450k methylation analysis for the anaplastic PXA (anaplastic PXA01), 11
PXA and 50 pediatric GBM through the pipeline ( Figure S3 , Data S1
[Statistical data processing for differential methylation]).
Tumor showed the characteristic histological features of ana- Table S7 ). Methylation levels were measured using the CpG assay of PyroMark Q96, and mean methylation levels of all CpG sites included in each assay were used to represent the methylation status of each gene. The methylation levels at those CpG sites measured by pyrosequencing showed a certain concordance with that of the 450K array ( Figure S7C ). Our study suggested that anaplastic PXA may consist of a clinically and biologically heterogeneous group of tumors, and genome-wide methylation profiling may help identify those. profiling showed that epithelioid GBM may be divided into PXA and GBM, suggesting that there may be distinct subgroups. 9 Our case strongly suggests that DNA methylation-based diagnosis can more precisely classify anaplastic PXA, as has recently been proposed. 5 It is unlikely that histology alone is sufficient to diagnose anaplastic PXA, as pleomorphic gliomas with anaplastic features include both anaplastic PXA and epithelioid GBM. The BRAF V600E status alone is not sufficient as a diagnostic or prognostic biomarker either. 10 Our study suggested that anaplastic PXA may consist of a clinically and biologically heterogeneous group of tumors, and genome-wide methylation profiling may help identify those. Full implementation of the molecular approach is likely to be the key to predict prognosis and decide treatment strategy for PXA patients in the future.
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